Please download the PDF here and read it!
As part of its growing commitment to the Asian market, IBSA will participate once again in CPhI Japan 2025, a major international event for the pharmaceutical industry in the APAC region. With more than 20,000 attendees and representatives from over 50 countries expected, this prestigious exhibition provides an essential platform for IBSA to strengthen its position in the region and highlight its innovative solutions tailored to meet the diverse needs of patients and healthcare professionals worldwide.
“Japan and the broader Asia-Pacific region represent significant growth opportunities for IBSA,” says Andrea Taborelli, Senior Business Development and Licensing Manager. “CPhI Japan is the perfect stage for us to engage with key players in the industry, including potential partners, distributors, and clients, and demonstrate how our cutting-edge technologies meet global market needs.”
Spotlight on Key Products
At the Tokyo exhibition, IBSA will focus on its flagship products in the osteoarticular field, particularly Sinovial® HL and Sinogel®. These pre-filled syringes for intra-articular injections, based on hybrid hyaluronic acid, offer effective solutions for pain relief and improved mobility in patients with degenerative or post-traumatic conditions and tendinopathies associated with joint disability. Developed using patented NAHYCO® HYBRID TECHNOLOGY, these products achieve a high concentration of hyaluronic acid without compromising ease of use or safety during injection.
The same technology is also the foundation of two other flagship products that IBSA intends to highlight. These include Ialuril® Prefill, pre-filled syringes indicated to re-establish the glycosaminoglycan layers of the urothelial vesical tissue in cases where their loss can cause frequent and recurring problems. Another key product is Hyaluxelle®, pre-filled syringes containing a combination of high and low molecular weight hyaluronic acid, specifically developed for adult women to treat the vulvar vestibule in cases of vaginal atrophy, dryness, burning, or itching (non-infectious), as well as pain during intercourse.
Another standout product is IBSA’s Sildenafil Orodispersible Film, designed for the treatment of erectile dysfunction. This innovative delivery method ensures rapid bioavailability and improved patient compliance, offering convenience by eliminating the need for water during administration. IBSA will also showcase its growing range of food supplements, produced in pharmaceutical forms like orodispersible films and softgel capsules. One particularly noteworthy product is Iron, a food supplement based on iron and folic acid, specifically developed for individuals diagnosed with iron deficiency.
Strengths for International Partners
IBSA’s ongoing success in global markets is rooted in its technological advancements, consistent investment in R&D, and a unique ability to develop patient-centered solutions. The orodispersible film technology exemplifies this focus: an ultra-thin strip the size of a postage stamp that dissolves within seconds on the tongue, providing rapid bioavailability and greater ease of use.
The NAHYCO® HYBRID TECHNOLOGY used in hyaluronic acid-based products further sets IBSA apart. This proprietary innovation combines high and low molecular weight hyaluronic acid to obtain unique hybrid complexes capable of effectively mimicking the physical and mechanical properties of healthy synovial fluid, ensuring optimal effectiveness and patient satisfaction.
In addition to its technological edge, IBSA provides robust support for its partners, including scientific validation through clinical studies and promotional tools developed by its International Marketing team. “Our technologies and comprehensive partner support make IBSA a trusted name in the pharmaceutical industry and an attractive partner for foreign distributors” adds Taborelli.
Commitment to Global Expansion
IBSA’s participation in CPhI Japan aligns with the company’s broader internationalization strategy. Over the past decade, the group has expanded significantly, establishing subsidiaries across Europe, the US, and China. However, to complement this process, the group has also been actively seeking partners and international distributors for licensing agreements in countries where it does not operate directly with its branches. Now the Group has identified the Asia-Pacific as a strategic region for expansion, targeting countries like Japan, Malaysia, Singapore, Hong-Kong, the Philippines, Thailand, South Korea, China, and Australia.
Participation in CPhI Japan underscores IBSA’s commitment in delivering its high-quality pharmaceutical products to new audiences, providing a gateway to deepen relationships and forge new collaborations within the Asian market.
Contacts
Business.Development@ibsa.ch
www.businessdevelopment.ibsagroup.com
